

C¹

The last few years have heralded an unprecedented increase in gene sequencing and identification as exemplified by the announcement of the complete genome sequence of prokaryotic and eukaryotic cells and organisms including the model eukaryote *C. elegans* (Science, 11 Dec 1998). The sequencing of the human genome continues to accelerate with completion projected for 3-4 years time. This growing DNA sequence data is being used as a platform for the systematic investigation of gene (mRNA) expression and function. Such investigation combined with associated informatics are transforming basic biological research and will transform the drug discovery, development and delivery processes. However, it has become increasingly apparent that DNA sequence data in itself often provides little information about the function of the encoded protein products. Furthermore, measurement of gene expression at the mRNA level does not always give an accurate representation of the expression of the corresponding proteins nor indeed of the extent to which they may be post-translationally modified. Importantly, it is predominantly proteins that execute biological function. Hence, there is a growing desire to analyse, in a systematic and comprehensive manner, the expression and activity of the protein products of an organism's genome – this aim provides a working definition of proteome analysis (or proteomics) (see Pennington et al. Proteome analysis: from protein characterization to biological function. Trends Cell Biol. 7, 168-173 and references therein). It is important to emphasise that the activity of individual proteins may be regulated by a number of different mechanisms including their level of expression within individual tissues or cells, the extent and type of post-translational

modification, their subcellular localization and their interactions with other proteins.

Proteomics therefore encompasses a broad range of experimental approaches.

(Page 20, lines 19-26)

The predominant peptide masses from the spectrum in Figure 5A and 5B were selected

'blind' (after subtraction of peaks shown to originate from residual non-specific protein

binding by use of an appropriate control – proteins recovered from wells in which no

antibody has been immobilized) and used to search protein sequences databases using

publicly available software. Again BSA was identified as the 1st ranging protein.

1. (Twice Amended)) A method of selection and/or identifying one or more protein affinity ligands, wherein the affinity ligands are antibodies, that bind to one or more proteins of interest, comprising the steps of:

(A) obtaining a real or theoretical mass spectrometry based characterization of the one or more proteins by either:

i. Subjecting the one or more proteins to a mass spectrometry based characterization; or

ii. Predicting the mass spectrometry based characterization from known data;

(B) utilizing the one or more proteins either individually or as a mixture to:

i. Generate one or more antibodies thereto by immunization; and/or

ii. Select, using a single or multiple rounds of binding, one or more antibodies thereto;

(C) screening to one or more antibodies generated in step B(i) and/or multiple antibodies selected by step (B)(ii) by:

i. adding a mixture of proteins or the one or more proteins individually to the one or more antibodies generated in step (B)(i) or the one or more antibodies selected in step (B)(ii), each antibody being used individually, and

ii. after removing any proteins which have not bound, eluting the at least one protein has bound;

(D) subjecting the at least one eluted protein to mass spectrometry based characterization; and

A3
cont.
C4
1. (E) by comparing the mass spectrometry based characterization obtains in steps (A) and (D), selecting and/or identifying that at least one antibody that binds to the one or more proteins of interest.

2. (Once Amended) A method as claimed in claim 1 wherein the one or more proteins of interest have been previously resolved by 2D electrophoresis.

3. (Twice Amended) A method as claimed in claim 1 wherein the one or more proteins of interest are present in a mixture of proteins.

4. (Twice Amended) A method as claimed in claim 1 wherein the method is a method for selecting and identifying protein affinity ligands to a plurality of proteins.

5. (Twice Amended) A method as claimed in claim 1 wherein the antibodies optionally generated in step (B)(i) are immobilized on a support comprising nitrocellulose or PVDF.

6. (Once Amended) A method as claimed in claim 7 wherein the support upon which the antibodies are immobilised and the nitrocellulose or PVDF are treated with an oligosaccharide or polyvinylpyrrolidone solution to block any remaining binding sites.

12. (Once Amended) A method generating monoclonal antibodies to one or more targeted proteins comprising the steps of:

- (a) resolving a complex protein mixture;
- (b) subjecting the resolved protein(s) to peptide mass fingerprinting to obtain a peptide mass profile or obtain a theoretical peptide mass profile;
- (c) utilizing one or more of the resolved proteins to generate one or more monoclonal antibodies thereto;
- (d) adding the or another complex protein mixture to the one or more monoclonal antibodies generated in Step (c), to select those proteins which bind the one or more monoclonal antibodies, and subjecting the selected proteins(s) to peptide mass fingerprinting to obtain a peptide mass profile;
- (e) comparing the peptide mass profiles obtained in steps (b) and (d); and
- (f) selecting one or more monoclonal antibodies of interest.

13. (Once Amended) A method of generating an antibody library comprising the steps of:

- (a) resolving a complex protein mixture and subjecting the resolved protein(s) to peptide mass finger printing to obtain a peptide mass profile; or
- (b) obtaining a theoretical peptide mass profile for a protein which is sought;
- (c) utilizing the or the other complex protein mixture to generate one or more monoclonal antibodies thereto;
- (d) adding the one or the other complex protein mixture to the one or more monoclonal antibodies generated in Step (c) to select those proteins which bind the one or

DB
AE
cont. prep
more monoclonal antibodies, and subjecting the selected protein(s) to peptide mass fingerprinting to obtain a peptide mass profile;

(e) comparing the peptide mass profiles obtained in steps (a or b) and (d); and

(f) identifying the monoclonal antibodies of interest.

CG
17. (Twice Amended) A method as claimed in claims 1, 2, 7, 8, or 9 wherein the mass spectrometry based characterization is obtained by mass spectrometry.

MMF 5
18. (Twice Amended) A method as claimed in claims 1, 2, 7, 8, or 9 further comprising the use of automated well plate handling technology and automated high-throughput mass spectrometry.

CG
29. (Once Amended) A method as claimed in claim 2 wherein the method is a method for selecting and identifying protein affinity ligands to a plurality of proteins.

SGP
34. (Once Amended) A method of selecting and/or identifying at least one antibody which binds at least one protein of interest, comprising the steps of:

(a) obtaining a theoretical mass spectrometry-based characterization of a target protein;

(b) providing an antibody which selectively binds to said target protein;

(c) isolating and collecting said target protein through affinity binding with said antibody;

com. E7

(d) analyzing said collected target protein for said pre-selected mass spectrometry-based characterization; and

(e) comparing the mass spectrometry-based characterization obtained in step (d) with the theoretical mass spectrometry-based characterization of step (a).

112 Sub 310

37. (New) A method as claimed in claim 1 wherein an eluting agent is further provided for eluting protein from antibody-protein complexes.

38. (New) A method as claimed in claim 37 wherein the eluting agent is formic acid.

39. (New) A method as claimed in claim 8 wherein an eluting agent is further provided for eluting protein from antibody-protein complexes.

40. (New) A method as claimed in claim 39 wherein the eluting agent is formic acid.

41. (New) A method as claimed in claim 19 wherein an eluting agent is further provided for eluting protein from antibody-protein complexes.

42. (New) A method as claimed in claim 41 wherein the eluting agent is formic acid.

43. (New) A method as claimed in claim 20 wherein an eluting agent is further provided for eluting protein from antibody-protein complexes.

44. (New) A method as claimed in claim 43 wherein the eluting agent is formic acid.

45. (New) A method as claimed in claim 21 wherein an eluting agent is further provided for eluting protein from antibody-protein complexes.

46. (New) A method as claimed in claim 45 wherein the eluting agent is formic acid.
